Now I know you are a liar.
Sales are ramping up. Sales for 9 months increased over 100% from a year earlier.
Feb 3: ":Guided Therapeutics, Inc. (GTHP) (GTHP) today announced that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan. The company has been in communication with the agency and is hoping to receive the agency’s decision within the next several weeks."
Too many shares?
You must be referring to GENE : 1,202,025,198 ordinary shares.
That's 1.2 BILLION!
Investors will be working in the dark, taking a leap of faith.
Never try to catch a falling knife.
The bottom is always a lot lower than you think.
Buy stocks that are climbing, not ones that are sinking.
Until then, step aside, you'll get crushed by the drop.
Make money on other stocks. Someone mentioned GTHP.
It could be the real deal. Even if it's just a pump & dump,
you'll be getting in near the bottom and you'll be playing
along instead of being played.
If the discounted offering is at .75, they will short the #$%$ out of the tock at these levels and then cover with the shares that they agreed to buy at .75 from the Company.
INO was overpriced $900M and it's still overpriced at $400M and it will be overpriced at $100M.
There's nothing here but hype, and hype is worthless.
Why has Inovio not completed even one Phase 3 trial?
Why have all the partners terminated the agreements?
The answer to both questions is the same: Inovio has nothing that works.
That was the low for December only?
But you believed there would be a lower low in January - February?
Is that what you are saying?
"For submissions that do not require Advisory Committee input, FDA will issue a MDUFA decision within 180 FDA Days for: 70% of submissions received in FY 2013; 80% of submissions received in FY 2014 and FY 2015; and 90% of submissions received in FY 2016 and FY 2017."
(I guess we're in the 20% of filers.)
"For all PMA submissions that do not reach a MDUFA decision by 20 days after the applicable FDA Day goal, FDA will provide written feedback to the applicant to be discussed in a meeting or teleconference, including all outstanding issues with the application preventing FDA from reaching a decision. The information provided will reflect appropriate management input and approval, and will include action items for FDA and/or the applicant, as appropriate, with an estimated date of completion for each party to complete their respective tasks. Issues should be resolved through interactive review. If all of the outstanding issues are adequately presented through written correspondence, FDA and the applicant can agree that a meeting or teleconference is not necessary."
(If the MDUFA is not received by Feb 20th, there's a problem.)
"FDA will issue a MDUFA decision within 180 FDA Days for: 85% of submissions received in FY 2013; 90% of submissions received in FY 2014 and FY 2015; and 95% of submissions received in FY 2016 through FY 2017."
(We're in the 10%.)
So what? Somebody has to own the stock. Index funds hold a large chunk because they have to.
This is a diversion from Inovio's accomplishments, or lack there of.